Skip to main content
Chest logoLink to Chest
. 2019 Oct 31;157(3):654–664. doi: 10.1016/j.chest.2019.10.015

Mobile Health Technologies in Cardiopulmonary Disease

Grant E MacKinnon a, Evan L Brittain b,∗
PMCID: PMC7078586  PMID: 31678305

Abstract

Mobile health (mHealth) technologies are modernizing medicine by affording greater patient engagement, monitoring, outreach, and health-care delivery. The cardiopulmonary fields have led the integration of mHealth into clinical practice and research. mHealth technologies in these areas include smartphone applications, wearable devices, and handheld devices, among others, and provide real-time monitoring of numerous important physiological measurements and other key parameters. Use of mHealth-compatible devices has increased in recent years, and age and socioeconomic gaps of ownership are narrowing. These tools provide physicians and researchers with a better understanding of an individual’s health and well-being. mHealth interventions have shown utility in the prevention, monitoring, and management of atrial fibrillation, heart failure, and myocardial infarction. With the growing prevalence of cardiopulmonary disease, mHealth technologies may become a more essential element of care within and outside of traditional health-care settings. mHealth is continuously developing as a result of technologic advancements and better understandings of mHealth utility. However, there is little regulation on the mHealth platforms available for commercial use and even fewer guidelines on implementing evidence-based practices into mHealth technologies. Online security is another challenge and necessitates development in data collection infrastructure to manage the extraordinary volume of patient data. Continued research on long-term implications of mHealth technology and the integration of effective interventions into clinical practice is required.

Key Words: cardiovascular disease, digital health, mHealth, mobile health

Abbreviations: AF, atrial fibrillation; app, application; CR/SPP, cardiac rehabilitation and secondary prevention program; CVRF, cardiovascular risk factor; FDA, Food and Drug Administration; HF, heart failure; mHealth, mobile health; PH, pulmonary hypertension; PPG, photoplethysmography; QOL, quality of life; RCT, randomized controlled trial


Most decisions impacting an individual’s health occur outside of hospital and clinic settings (eg, social determinants of health). This demonstrates the necessity for tools to empower people to make healthy decisions at home. US health care is placing greater emphasis on preventative and value-based measures, exhibited by the growth of accountable care organizations.1 Health-care systems and physicians now have more responsibility to deliver personalized care in this modern age of medicine. Mobile health (mHealth) technologies have emerged as primary drivers of improving patient health by facilitating behavioral change and are increasingly used in health-care delivery, as depicted in Figure 1.

Figure 1.

Figure 1

Potential mobile health applications in various stages of cardiovascular health-care delivery. CVD = cardiovascular disease; CVRF = cardiovascular risk factor; EHR = electronic health record.

mHealth is defined by the World Health Organization as “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices.”2 It is estimated 81% of US adults owned a smartphone in 2018 compared with 35% in 2011. Additionally, age and socioeconomic gaps of smartphone use are narrowing.3 Newer devices with increasingly powerful computing abilities allow for the transmission of patient data in real time and the potential for transforming the paradigm of health care from traditional health-care settings to a patient’s hands.

In 2017, there were > 318,000 mHealth applications (apps) available for download, nearly double the number in 2015.4 Approximately 60% of US adults have downloaded a health or wellness app.3 Unique features of mHealth apps include gamification, social elements, and rewards, specifically financial incentives from insurance companies. Most these apps track an individual’s weight but lack evidence-based strategies to promote weight loss.5 Health agencies are pushing for increased app regulation; however, the US Food and Drug Administration (FDA) endorses a risk-based approach of only regulating apps with possible harm to users.6 The global mHealth app market size was valued at $12.4 billion in 2018 and is estimated to grow to $236 billion by 2026.4

Wearable mHealth technologies include smartwatches, handheld devices, and skin patches, among others. Approximately 25% of US adults use wearables at least once a month, driven by smartwatch popularity with young adults. About 45% of smartwatch owners use their smartwatch as an activity tracker, second only to messaging notifications.7 Reported physiological parameters measurable by wrist-worn watches include pulse, BP, heart rhythm, cardiac output, body temperature, respiratory rate, oxygen saturation, blood glucose, physical activity, sleep patterns, and stress level.8 The market for wearable mHealth technology is expected to be worth $34 billion in 2020.9

Methods

This review is not designed as a systematic review but instead is a distillation of high-quality available literature on mHealth and cardiopulmonary care. Primary literature was acquired through the Cochrane Library and PubMed databases by searching for articles with “mobile health” or “mHealth” in the title. Randomized controlled trials (RCTs) were selected based on evidence, year published, and number of citations and can be found in Table 1.

Table 1.

Randomized Controlled Trials Investigating mHealth Efficacy

Study/Year Subject Characteristics mHealth Interventions Findings
Physical activity
 Cadmus-Bertram et al13/2015 BMI ≥ 25 kg/m2, N = 51 Web-based tracking and accelerometer vs standard pedometer
  • •

    Increased MVPA in web-based tracking group by 62 min/wk and daily steps by 789 compared with nonsignificant increases in control group

 Harries et al15/2016 Age 18-40 y, N = 152 App and personalized or social feedback vs usual care
  • •

    Personalized and social feedback increased daily steps 60% and 69%, respectively

  • •

    No statistically significant difference between personalized and social feedback

 Martin et al14/2015 Age 18-69 y, N = 48 Wearable and personalized messaging vs wearable alone
  • •

    Personalized text messaging increased daily steps over those not receiving texts and blinded control subjects by 2,534 and 3,376 steps, respectively

Obesity
 Godino et al18/2016 Overweight college students, N = 404 Smartphone apps, text messaging, health coach telecommunication vs health and wellness website
  • •

    Weight loss was significantly greater in the intervention group at 6 and 12 mo but not significant at 18 and 24 mo

 Spring et al20/2018 N = 212 Smartphone app vs contact-control sleep exercises
  • •

    App increased MVPA and fruit and vegetable intake and decreased sedentary time and saturated fat intake

Hypertension
 Varleta et al25/2017 HTN, N = 314 Text messaging vs usual care
  • •

    Text messaging resulted in increased antihypertensive drug adherence at 6 mo

 Kim et al26/2016 HTN, N = 95 Home BP monitoring and smartphone app vs usual care
  • •

    mHealth led to improvements in BP, smoking habits, and alcohol consumption

  • •

    No differences in medication adherence were observed

Smoking cessation
 Bricker et al22/2014 N = 196 SmartQuit smartphone app vs QuitGuide smartphone app
  • •

    SmartQuit group opened app more than QuitGuide group (37 times vs 15 times, respectively)

  • •

    Quit rates were 13% in SmartQuit vs 8% in QuitGuide (95% CI, 0.8-10.3)

 Cobos-Campos et al23/2017 N = 320 Text messaging and health advice vs health advice alone
  • •

    Higher rates of smoking cessation at 6 and 12 mo in intervention group

  • •

    Subjects with mild tobacco dependence had higher rates of smoking cessation

Diabetes
 Quinn et al29/2016 Type 2 diabetes,
N = 118
Mobile phone coaching and web portal vs usual care
  • •

    Intervention found greater decline in hemoglobin A1C at 12 mo

  • •

    Intervention was effective in older (age 45-64 y) and younger people (age < 45 y)

 Baron et al31/2017 Hemoglobin A1C > 7.5% and insulin-taking, N = 81 Mobile-phone transmitted blood glucose meters and BP monitors vs usual care
  • •

    Intervention did not show significant changes in hemoglobin A1C at 9 mo

  • •

    Borderline significant changes in BP control (P = .054) and mental-health QOL (P = .057) were observed

Atrial fibrillation
 Halcox et al38/2017 Age ≥ 65 y and CHADS-VASc score ≥ 2, N = 1,001 AliveCor monitor vs usual care
  • •

    Monitored group found increased AF diagnosis in 12 mo

  • •

    No difference in stroke/transient ischemic attack/systemic embolic events

 Steinhubl et al39/2018 Age > 75 y or comorbidities, N = 2,659 ECG patch vs usual care
  • •

    ECG patch led to increased diagnosis of AF, anticoagulant use, outpatient cardiology visits, and primary care visits

  • •

    No difference in number of ED visits and hospitalizations

Heart failure
 Chaudhry et al46/2010 HF, N = 1,653 Daily symptom and weight collection vs usual care
  • •

    Telemonitoring did not improve readmission rates or all-cause deaths

 Dendale et al45/2012 HF, N = 160 Telemonitoring vs usual care
  • •

    Telemonitoring group with significantly lower all-cause mortality and days lost to dialysis, hospitalization, or death

Myocardial infarction
 Johnston et al50/2016 Post-MI, N = 174 Smartphone app vs simplified drug adherence e-diary
  • •

    App achieved greater drug adherence

 Chow et al51/2015 Post-MI, N = 710 Text messaging vs usual care
  • •

    Text messaging led to a reduction in LDL, systolic BP, and BMI

  • •

    Text messaging led to increases in physical activity and smoking cessation

COPD
 Tsai et al52/2017 COPD, N = 37 Home-based telerehabilitation vs usual care
  • •

    Telerehabilitation resulted in increased endurance in shuttle walk test time

  • •

    No difference in daily steps was observed

 Vorrink et al53/2016 COPD, N = 157 Smartphone app and physiotherapy website vs usual care
  • •

    Intervention found no differences in daily steps or functional exercise capacity

  • •

    Intervention led to a decrease in lung function

Cardiac rehabilitation
 Varnfield et al66/2014 Post-MI, N = 120 Smartphone-based CR vs center-based CR
  • •

    Smartphone-based CR with higher uptake, adherence, and completion rates

  • •

    Smartphone-based CR demonstrated significant improvements in 6MWD, weight loss, emotional state, and QOL

 Widmer et al68/2017 Post-PCI, N = 80 Center-based CR and smartphone-based CR vs center-based CR alone
  • •

    Inclusion of smartphone-based CR showed improved weight loss and a nonsignificant reduction in CV-related rehospitalizations (P = .054)

6MWD = 6-min walk distance; AF = atrial fibrillation; app = application; CHADS-VASc = stratification score for predicting ischemic stroke risk; CR = cardiac rehabilitation; CV = cardiovascular; HF = heart failure; HTN = hypertension; mHealth = mobile health; LDL = low-density lipoprotein; MI = myocardial infarction; MVPA = moderate to vigorous physical activity; PCI = percutaneous coronary intervention; QOL = quality of life.

Cardiovascular Risk Factors

In 2014, the American Heart Association hosted an inaugural interdisciplinary forum involving 130 leaders and 40 speakers to identify a framework for integrating mHealth into routine practice. The concluding recommendation focused on using the American Heart Association’s Life's Simple 7 for the prevention and treatment of cardiovascular disease.10 Correspondingly, popular mHealth apps target modifiable cardiovascular risk factors (CVRFs), namely physical inactivity, obesity, smoking, hypertension, and diabetes.

Physical Activity

mHealth technologies have demonstrated superior accuracy of measuring physical activity compared with self-reporting, the latter of which routinely results in overestimation of activity.11 Beyond their monitoring capacities, mobile apps and wearables with personalized feedback have shown success in increasing daily steps and weekly minutes of moderate to vigorous physical activity.12,13 The mActive trial demonstrated an increase in daily steps with an activity tracking and personalized text messaging intervention, whereas no change in daily steps was observed in activity tracking alone.14

Some apps include social networks with peer comparison and connections to social media. Apps with social feedback were beneficial in mothers and older adults whereas no effect was observed in young adult men.15,16 Mothers also reported significant reductions in depression scores, presumed to be the result of increased physical activity.16 mHealth interventions potentially may improve multiple CVRFs, as illustrated by the mActive-Smoke study finding an inverse relationship between smoking urge scoring and steps taken 30 to 120 min prior to the urge reporting.17

Obesity

mHealth technologies targeting obesity include personalized text messaging, step count notifications, health coaching telecommunication, diet tracking, social networking, and financial incentives. These interventions have demonstrated short-term success but were ineffective in maintaining weight loss beyond 12 months, with one study showing normalization of the intervention and control groups at 3 months.18,19 mHealth apps targeting eating behaviors found sustained success in reaching diet guideline recommendations for fruit, vegetable, and saturated fat intake; however, app use decreased with time.20

Smoking

Smoking cessation resources have primarily focused on apps that allow users to develop a quit plan and track their progress. Many apps provide access to community resources, such as toll-free quit-lines and free nicotine replacement therapy. Apps using cognitive behavioral therapy and acceptance and commitment therapy have demonstrated increased rates of smoking cessation up to 6 months. In addition, apps using acceptance and commitment therapy have shown greater user engagement compared with an app following the US clinical practice guidelines. People with less tobacco dependence were found to have a higher likelihood of success.21, 22, 23 A pitfall of most studies investigating smoking cessation apps is the reliance on self-reporting for quit rates.

Hypertension

Over 40 million primary care visits occur annually in the United States among people with documented hypertension. Transitioning hypertension management from clinic visits to home monitoring would substantially reduce costs and unneeded appointments.8 Compared with usual care of office visits, self-monitoring of BP has shown significantly improved BP control.24 The phenomena of whitecoat hypertension, or hypertension only evident in health-care settings, and masked hypertension, or hypertension not apparent in clinic visits but present elsewhere, further demonstrate the potential value of home monitoring.

mHealth technologies in this area include BP monitoring devices connected to smartphones, text messaging medication reminders, and apps promoting a low-salt diet. Studies have shown a reduction in BP with variable efficacy in improving medication adherence.25,26 Improvements in BP control without improvements in medication adherence were speculated to be a result of reductions in cigarette and alcohol use, suggesting such interventions may facilitate behavioral change beyond the primary target of BP control.26 Proteus Discover is a novel digital health platform consisting of sensor-containing medicines, a patient app, and a provider portal and has shown greater control of hypertension compared with usual care. Once ingested, sensor-containing medicines transmit signal to a smartphone, providing insight into medication-taking behavior and facilitating therapy optimization.27

Diabetes

Management of diabetes has improved with technologic advances in insulin administration. New generations of blood glucose monitors, including transdermal monitoring patches, transmit glucose data automatically, eliminating manual monitoring and documentation. Additionally, software interfaces provide personalized education based on recent glucose measurements.28 Telecommunication and smartphone apps show inconclusive evidence on improving hemoglobin A1C control; however, most studies are of limited size. However, these interventions show improvements in weight loss, quality of life (QOL), and depression scores.29, 30, 31 Emerging technologies include noninvasive spectroscopic glucose measurements with accuracy equivalent to finger stick devices.32

Remote Monitoring

There is growing use of mHealth technologies in remote patient monitoring and surveillance for disease decompensation. Most studies in this domain concern the identification of arrhythmias and monitoring people with or for heart failure (HF) and myocardial infarction. A paucity of data concerning lung diseases exist, but there is increasing investigation of mHealth technologies in pulmonary hypertension (PH) and COPD. Development in mHealth monitoring may lead to improved diagnosis, reduced hospitalizations, and improved survival. An overview of clinical trials studying mHealth efficacy in managing these conditions, along with emerging mHealth technologies, is subsequently discussed.

Atrial Fibrillation

The prevalence of undiagnosed atrial fibrillation (AF) in the United States is nearly 600,000 people, and the medical cost burden is $3.1 billion. Over one-half of the undiagnosed AF population is at moderate to high risk of stroke.33 The paroxysmal nature of AF, especially early in the disease, leads to its underdiagnosis and can be more readily identified through improved and prolonged monitoring of people at risk for AF. Detection rates of AF by an insertable cardiac monitor increased from 6.2% to 40.0% when monitoring was extended from 30 days to 30 months.34

Remote monitoring for arrhythmia detection has been available since Holter monitors were first introduced in 1949, followed by implantable loop recorders in 1992.35 Modern mHealth technologies include handheld single-lead and multiple-lead ECG recorders, mobile phone-based photoplethysmography (PPG), and wearable device-based PPG. Handheld ECG recorders require an external device connected to a smartphone by Bluetooth. PPG is an optical technique analyzing skin color changes and light absorption, most often in the pad of the index finger, and does not require external monitors. A limitation of PPG is its susceptibility to motion artifacts caused by hand movements. Nevertheless, a significant strength of PPG is the secondary analysis for the detection of arteriosclerosis or arterial stiffness.36

The most-studied handheld ECG recorders and mobile phone-based PPG both yield sensitivities and specificities of > 90% in detecting AF. One such device, the AliveCor ECG recorder, has a reported sensitivity of 98%, specificity of 97%, and accuracy up to 300 beats/min.37 Monitoring people at risk for AF with handheld ECG devices and mobile phone PPG has shown increased detection of AF, anticoagulation use, health-care utilization, and QOL. However, there was no significant change in stroke incidence at 1 year. The multifaceted outcomes demonstrate AF monitoring may facilitate other related interventions, such as medication adherence.38, 39, 40 Handheld ECG recorders have shown promise in detecting atypical AF, or AF with symptoms other than palpitations.40 Beyond arrhythmia detection, ECGs obtained remotely may suggest electrolyte abnormalities or drug toxicities; however, few studies have investigated this capability.37

The Apple Heart Study began in 2017 and completed data collection in early 2019. It is the largest investigation of mHealth AF detection with 419,297 self-enrolled subjects. The study used the Apple Watch paired with the Heart Study iOS app. PPG detection of repeated irregular pulses triggered a notification for the subject to contact the study physician for a video consultation on the necessity of further arrhythmia workup. Approximately 0.5% of subjects received a notification and its positive-predictive value for diagnosis of AF was 84%. Limitations included relying on self-reported data and nearly one-half of subjects failing to contact the study physician after receiving a notification. The Apple Heart Study demonstrates the utility of remote AF detection; however, improved telecommunication avenues are necessary.41

HF

HF affects > 5.7 million US adults and is associated with high health-care utilization. HF complications lead to approximately 1 million hospitalizations annually and have a 30-day readmission rate of 27%, the highest among all chronic medical diseases.42 Home-based interventions may be a fruitful target to reduce and shorten hospitalizations. The Heart Failure Matters program, introduced by the European Society of Cardiology, is an example of a platform to engage people at home. Users are provided symptom diaries, appointment reminders, medication charts, and educational videos on HF. The Heart Failure Matters website43 attracts > 2.5 million people annually; however, its effectiveness has not been prospectively validated.

Daily weight monitoring is recommended to people with HF to monitor volume status, but compliance is a challenge. mHealth HF technologies have targeted adherence to daily weights through programed reminders and electronic charting of measurements, manually or automatically through Bluetooth-capable scales. Additionally, some apps alert physicians and HF clinics if predefined weight limits are exceeded. mHealth telemonitoring, symptom diaries, and mobile phone alerts have shown improvements in daily weight monitoring, QOL, brain-natriuretic peptide levels, and left ventricular ejection fraction.44,45 Of note, a large RCT investigating daily phone calls did not show a difference in mortality or hospitalizations, but its generalizability was limited by significant dropout rates.46

In addition to improving adherence to daily weight monitoring, mHealth tools may improve risk prediction for hospitalization. Algorithms based on weight patterns predicted HF events with more sensitivity than guideline methods.47 An algorithm using a wearable device had a specificity of 90% for the prediction of HF decompensation.48 Devices measuring thoracic impedance have been developed; however, more research is necessary to assess its utility in HF.

Myocardial Infarction

mHealth tools may permit improved triage and treatment of myocardial infarction. Bluetooth-enabled defibrillators can transmit 12-lead ECGs via emergency personnel mobile phones to off-site cardiologists. Direct communication with cardiologists led to significantly shorter door-to-balloon times, lower peak troponin, higher left ventricular ejection fraction, and shorter length of stay.49 Appropriately triaged patients may decrease unnecessary laboratory costs and reduce the burden on acute care services. mHealth interactive apps created for people post-myocardial infarction are successful in increasing medication adherence and reducing CVRFs.50,51

COPD

mHealth in COPD has demonstrated varying success in improving functional exercise capacity. A study of web-based telecommunication exercise training showed an improvement in endurance, assessed by a shuttle walk test.52 However, a study using an mHealth app and physiotherapist monitoring website found no improvement in functional exercise capacity after a period of remotely administered pulmonary rehabilitation.53 Additional mobile technologies include wireless pulse oximeters and spirometers, and their utility in COPD and other lung diseases is currently under investigation.54

PH

Impaired functional status is a hallmark of PH. Intensive inpatient-based exercise programs are highly efficacious in improving exercise capacity.55 More practical, home-based interventions are being investigated. Clinical trials currently in recruitment are studying the utility of a text messaging-based behavioral change intervention coupled with a wearable accelerometer that transmits real-time activity data (eg, Fitbit) in an effort to increase step counts, exercise capacity, and QOL in people with PH.56,57 Future trials may also incorporate a home-based 6-min walk test as an end point. Self-administered 6-min walk tests have shown highly reproducible results over a broad range of walk distances and correlated strongly with in-clinic 6-min walk tests in healthy people and in people with varying severities of HF or PH.58

Rehabilitation Programs

Cardiac and pulmonary rehabilitation and secondary prevention programs (CR/SPPs) can modify CVRFs and improve exercise capacity. Furthermore, participation in CR/SPPs reduces all-cause mortality after percutaneous coronary interventions by 45% to 47%.59 Additional benefits include decreased hospital readmission rates, improved medication adherence, and improved QOL.60,61 Despite these proven benefits, only 19% to 34% of people are eligible to participate in CR/SPPs.62 Barriers to participation include lack of patient-perceived need, lack of physician referrals, costs, hours of operation coinciding with work hours, and distance to CR/SPPs from home.63,64 Established by the US Department of Health and Human Services, the Million Hearts initiative declared a goal of increasing CR/SPP utilization to 70% of eligible people, which could prevent 25,000 deaths and 180,000 hospitalizations in the United States annually.62

A significant utility of mHealth is the delivery of accessible CR/SPPs to people otherwise not reached by traditional CR/SPPs. The inability to drive is one of the strongest predictors of nonparticipation in CR/SPPs, suggesting a potential role for remote interventions.65 When compared with traditional CR/SPPs, home-centered mHealth CR/SPPs demonstrated increased participation and completion rates. Improved health outcomes of functional capacity, weight loss, and mental health were also observed.66 The cost of delivery for a 6-week mHealth CR/SPP is lower than a 6-week traditional CR/SPP ($1,633 vs $1,845, respectively), and participant travel costs were significantly lower ($80 vs $400, respectively).67 mHealth CR/SPP apps provide motivational and educational materials, exercise prescriptions, and behavior change text messaging. Apps also serve as convenient means of reporting dietary and exercise habits. When augmented with traditional CR/SPPs, mHealth use led to increased weight loss compared with traditional CR/SPPs alone.68

Inpatient Apps

Although most mHealth technology supports care outside of the hospital, mHealth can improve patient monitoring and treatment within health-care settings. Examples of mHealth technology in physician hands include digital stethoscopes and mobile phone ultrasound. A feature of some digital stethoscopes is the selection of different frequencies to target organs individually. For example, a stethoscope frequency ranging from 20 to 420 Hz is more specific for heart sounds, whereas another range from 350 to 1,900 Hz is used for lung auscultation.69 Mobile phone ultrasounds demonstrate reliable accuracy in measuring left ventricular ejection fraction and detecting a number of pathologies, such as hydronephrosis, gallstones, abdominal aortic aneurysms, and intraabdominal fluid collections. Mobile phone ultrasounds may have significant practicality in rural settings. Limitations include a narrow field of vision, poor penetration, and poor visualization of solid organ parenchymal disease.70

mHealth wearables and handheld devices can monitor a patient’s vital signs, theoretically decreasing the necessity of telemetry or nursing checks. These measures may improve patient mobility and decrease falls in the hospital. Preliminary studies in wearable vital signs monitoring have demonstrated patient perception of enhanced safety and improved accuracy of vital sign measurements compared with nursing measurements; however, limited enrollment did not elucidate differences in primary outcomes such as length of stay or readmission rates.71,72 Furthermore, mHealth supports the transition of care out of the hospital by continuing patient monitoring. More research is required to assess the reliability of mHealth use in health-care settings, particularly when accuracy, precision, and timeliness are of extreme importance.

mHealth technologies are increasingly integrated into research capacities. Advantages of mHealth include improvements in surrogate end points (eg, physical activity), real-time data transmission, increased participant outreach, reduced time and costs for data collection, and enhanced trial recruitment.73 The MyHeart Counts Cardiovascular Health Study, Health eHeart Study, and Apple Heart Study enrolled 48,968, 66,788, and 419,297 participants, respectively.41,74,75 Disadvantages of mHealth include the price of the device, technologic skills requirement, lack of interoperability between devices, privacy concerns, and technical support.73 Software platforms, such as the ResearchKit developed by Apple, allow researchers to easily develop apps, surveys, and modules, and collect participant data on iOS devices.76

In the hands of patients, mHealth technologies can provide access to medical records, supported by roughly two-thirds of hospitals offering apps with this feature. CareKit, software developed by Apple for iOS devices, allows users to monitor their progress and share information with their care team. Features include tracking of care plans, symptoms, and medication regimens.76 mHealth is an avenue for increasing patient engagement in health maintenance and health-related decisions and may improve communication.

Conclusions and Limitations

mHealth is a developing domain and is projected to become more integrated into patient care and research.8 With increasing cardiac disease prevalence and costs of care, health-care systems are becoming more reliant on disease prevention. The United States falls short in evidence-based practices for improving health, such as preventative care guidelines and rehabilitation services. mHealth may prove to be a means of increasing patient engagement, and its community outreach facilitates more equitable and sustainable care. However, access to mHealth, unless supplemented financially, may limit its overall utility in the most vulnerable populations. It is unknown but conceivable that mHealth use in clinical trial settings may not reflect practical use, given that trial participants are typically more engaged than the general population.

mHealth technologies, particularly apps, are developing exponentially with little regulation of the tools available to the public. The FDA regulates medical apps, defined as apps intended to be used as an “accessory to a regulated medical device” or having the ability to “transform a mobile platform into a regulated medical device.” Apps that do not satisfy this definition are designated health apps and are not regulated as such. FDA regulation concerns app functionality and risk to user health instead of evaluating for evidence-based modalities in improving well-being.6 Furthermore, app developers can bypass FDA regulatory oversight by use of disclaimers stating the app is meant for entertainment and recreational use only.8

Significant concerns for those using mHealth technologies are online security and leaking of private information. Roughly 78% of US adults consider information stored in their mobile phones to be private, more than information stored in their computer.77 A study investigating privacy in the top 24 medicine-related apps available on the Android platform found that 19 (79%) shared user data outside of the app. Third parties marketed user data to 216 fourth parties, with only three fourth parties (1.4%) belonging to the health sector.78 Furthermore, portable devices storing personal information may be misplaced or stolen, creating another privacy concern. With the mass of data exponentially increasing, development of infrastructure to support privacy is necessary.

A potential concern is mHealth tools identifying more people in need of care, subsequently increasing demand for cardiac services that may not be available. In addition, there is little long-term data on the effect of mHealth interventions on hard clinical outcomes (eg, death, hospitalization) because most studies have focused on surrogate or intermediate end points. Other challenges include provider education on the continually emerging technology and integrating activity assessment into clinical workflow.

mHealth has the potential to transform health-care delivery. In anticipation for future developments and supporting the technology already present, increased regulation and support for evidence-based measures are necessary. Adequately powered RCTs studying the long-term effects of mHealth interventions on clinical outcomes will deliver greater insight into this promising field and help health-care systems and physicians provide the best personalized care possible with an engaged populace.

Acknowledgments

Financial/nonfinancial disclosures: The authors have reported to CHEST the following: E. L. B. served on an advisory board for Bayer and receives funding from the National Institutes of Health to study mHealth applications in pulmonary vascular disease. None declared (G. E. M.).

Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

Footnotes

FUNDING/SUPPORT: This work was supported by the National Institutes of Health [Grant R34 HL136989 to Dr Brittain].

References

  • 1.Muhlestein D., Saunders R.S., Richards R., McClellan M.B. Recent progress in the value journey: growth of ACOs and value-based payment models in 2018. HealthAffairs website. https://www.healthaffairs.org/do/10.1377/hblog20180810.481968/full/
  • 2.Kay M., Santos J., Takane M. New Horizons for Health Through Mobile Technologies. World Health Organization; Geneva, Switzerland: 2011. [Google Scholar]
  • 3.Silver L. Smartphone ownership is growing rapidly around the world, but not always equally. Pew Research Center website. https://www.pewresearch.org/global/2019/02/05/smartphone-ownership-is-growing-rapidly-around-the-world-but-not-always-equally/
  • 4.Mhealth apps market size, share & trends analysis report by type (fitness, lifestyle management, nutrition & diet, women's health, medication adherence, healthcare providers/payers), and segment forecasts, 2019 - 2026. Grand View Research website. https://www.grandviewresearch.com/industry-analysis/mhealth-app-market
  • 5.Edwards E.A., Lumsden J., Rivas C. Gamification for health promotion: systematic review of behaviour change techniques in smartphone apps. BMJ Open. 2016;6(10) doi: 10.1136/bmjopen-2016-012447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.U.S. Food and Drug Administration Device software functions including mobile medical applications. https://www.fda.gov/medical-devices/digital-health/mobile-medicalapplications
  • 7.Liu S. Owners' daily use of smartwatch functions in the United States in 2017. statista website. https://www.statista.com/statistics/741692/us-owners-daily-use-of-smartwatch-functions/
  • 8.Steinhubl S.R., Muse E.D., Topol E.J. The emerging field of mobile health. Sci Transl Med. 2015;7(283):283rv3. doi: 10.1126/scitranslmed.aaa3487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lamkin P. Wearable tech market to be worth $34 billion by 2020. Forbes website. https://www.forbes.com/sites/paullamkin/2016/02/17/wearable-tech-market-to-be-worth-34-billion-by-2020/
  • 10.Eapen Z.J., Turakhia M.P., McConnell M.V. Defining a mobile health roadmap for cardiovascular health and disease. J Am Heart Assoc. 2016;5(7) doi: 10.1161/JAHA.115.003119. pii: e003119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Bittel A.J., Elazzazi A., Bittel D.C. Accuracy and precision of an accelerometer-based smartphone app designed to monitor and record angular movement over time. Telemed J E Health. 2016;22(4):302–309. doi: 10.1089/tmj.2015.0063. [DOI] [PubMed] [Google Scholar]
  • 12.Maddison R., Pfaeffli L., Whittaker R. A mobile phone intervention increases physical activity in people with cardiovascular disease: results from the heart randomized controlled trial. Eur J Prev Cardiol. 2015;22(6):701–709. doi: 10.1177/2047487314535076. [DOI] [PubMed] [Google Scholar]
  • 13.Cadmus-Bertram L.A., Marcus B.H., Patterson R.E., Parker B.A., Morey B.L. Randomized trial of a fitbit-based physical activity intervention for women. Am J Prev Med. 2015;49(3):414–418. doi: 10.1016/j.amepre.2015.01.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Martin S.S., Feldman D.I., Blumenthal R.S. mActive: a randomized clinical trial of an automated mhealth intervention for physical activity promotion. J Am Heart Assoc. 2015;4(11) doi: 10.1161/JAHA.115.002239. pii: e002239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Harries T., Eslambolchilar P., Rettie R., Stride C., Walton S., van Woerden H.C. Effectiveness of a smartphone app in increasing physical activity amongst male adults: a randomised controlled trial. BMC Public Health. 2016;16:925. doi: 10.1186/s12889-016-3593-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mascarenhas M.N., Chan J.M., Vittinghoff E., Van Blarigan E.L., Hecht F. Increasing physical activity in mothers using video exercise groups and exercise mobile apps: randomized controlled trial. J Med Internet Res. 2018;20(5):e179. doi: 10.2196/jmir.9310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Silverman-Lloyd L.G., Kianoush S., Blaha M.J., Sabina A.B., Graham G.N., Martin S.S. mActive-Smoke: a prospective observational study using mobile health tools to assess the association of physical activity with smoking urges. JMIR Mhealth Uhealth. 2018;6(5):e121. doi: 10.2196/mhealth.9292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Godino J.G., Merchant G., Norman G.J. Using social and mobile tools for weight loss in overweight and obese young adults (project smart): a 2 year, parallel-group, randomised, controlled trial. Lancet Diabetes Endocrinol. 2016;4(9):747–755. doi: 10.1016/S2213-8587(16)30105-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Spring B., Duncan J.M., Janke E.A. Integrating technology into standard weight loss treatment: a randomized controlled trial. JAMA Intern Med. 2013;173(2):105–111. doi: 10.1001/jamainternmed.2013.1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Spring B., Pellegrini C., McFadden H.G. Multicomponent mhealth intervention for large, sustained change in multiple diet and activity risk behaviors: the make better choices 2 randomized controlled trial. J Med Internet Res. 2018;20(6) doi: 10.2196/10528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.McClure J.B., Heffner J., Hohl S., Klasnja P., Catz S.L. Design considerations for mhealth programs targeting smokers not yet ready to quit: results of a sequential mixed-methods study. JMIR Mhealth Uhealth. 2017;5(3):e31. doi: 10.2196/mhealth.6845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Bricker J.B., Mull K.E., Kientz J.A. Randomized, controlled pilot trial of a smartphone app for smoking cessation using acceptance and commitment therapy. Drug Alcohol Depend. 2014;143:87–94. doi: 10.1016/j.drugalcdep.2014.07.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Cobos-Campos R.L., Fernández de Larrinoa A.A., Moriñigo A.S., Diez N.P., Barandiaran F.A. Effectiveness of text messaging as an adjuvant to health advice in smoking cessation programs in primary care: a randomized clinical trial. Nicotine Tob Res. 2017;19(8):901–907. doi: 10.1093/ntr/ntw300. [DOI] [PubMed] [Google Scholar]
  • 24.McManus R.J., Mant J., Haque M.S. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312(8):799–808. doi: 10.1001/jama.2014.10057. [DOI] [PubMed] [Google Scholar]
  • 25.Varleta P., Acevedo M., Akel C. Mobile phone text messaging improves antihypertensive drug adherence in the community. J Clin Hypertens (Greenwich) 2017;19(12):1276–1284. doi: 10.1111/jch.13098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kim J.Y., Wineinger N.E., Steinhubl S.R. The influence of wireless self-monitoring program on the relationship between patient activation and health behaviors, medication adherence, and blood pressure levels in hypertensive patients: a substudy of a randomized controlled trial. J Med Internet Res. 2016;18(6):e116. doi: 10.2196/jmir.5429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Osterberg L., Raja P., Cruz M. First clinical evaluation of a digital health offering to optimize treating in patients with uncontrolled hypertension and type 2 diabetes. J Am Coll Cardiol. 2016;67(13):2028. [Google Scholar]
  • 28.Klonoff D.C. The current status of mhealth for diabetes: Will it be the next big thing? J Diabetes Sci Technol. 2013;7(3):749–758. doi: 10.1177/193229681300700321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Quinn C.C., Shardell M.D., Terrin M.L. Mobile diabetes intervention for glycemic control in 45- to 64-year-old persons with type 2 diabetes. J Appl Gerontol. 2016;35(2):227–243. doi: 10.1177/0733464814542611. [DOI] [PubMed] [Google Scholar]
  • 30.Wayne N., Perez D.F., Kaplan D.M., Ritvo P. Health coaching reduces hba1c in type 2 diabetic patients from a lower-socioeconomic status community: a randomized controlled trial. J Med Internet Res. 2015;17(10):e224. doi: 10.2196/jmir.4871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Baron J.S., Hirani S., Newman S.P. A randomised, controlled trial of the effects of a mobile telehealth intervention on clinical and patient-reported outcomes in people with poorly controlled diabetes. J Telemed Telecare. 2017;23(2):207–216. doi: 10.1177/1357633X16631628. [DOI] [PubMed] [Google Scholar]
  • 32.Singh S.P., Mukherjee S., Galindo L.H. Evaluation of accuracy dependence of raman spectroscopic models on the ratio of calibration and validation points for non-invasive glucose sensing. Anal Bioanal Chem. 2018;410(25):6469–6475. doi: 10.1007/s00216-018-1244-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Turakhia M.P., Shafrin J., Bognar K. Estimated prevalence of undiagnosed atrial fibrillation in the united states. PLoS One. 2018;13(4) doi: 10.1371/journal.pone.0195088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Reiffel J.A., Verma A., Kowey P.R. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the reveal AF study. JAMA Cardiol. 2017;2(10):1120–1127. doi: 10.1001/jamacardio.2017.3180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gussak I., Vukajlovic D., Vukcevic V. Wireless remote monitoring of reconstructed 12-lead ecgs after ablation for atrial fibrillation using a hand-held device. J Electrocardiol. 2012;45(2):129–135. doi: 10.1016/j.jelectrocard.2011.09.003. [DOI] [PubMed] [Google Scholar]
  • 36.Castaneda D., Esparza A., Ghamari M., Soltanpur C., Nazeran H. A review on wearable photoplethysmography sensors and their potential future applications in health care. Int J Biosens Bioelectron. 2018;4(4):195–202. doi: 10.15406/ijbsbe.2018.04.00125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Li K.H.C., White F.A., Tipoe T. The current state of mobile phone apps for monitoring heart rate, heart rate variability, and atrial fibrillation: narrative review. JMIR Mhealth Uhealth. 2019;7(2) doi: 10.2196/11606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Halcox J.P.J., Wareham K., Cardew A. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation. 2017;136(19):1784–1794. doi: 10.1161/CIRCULATIONAHA.117.030583. [DOI] [PubMed] [Google Scholar]
  • 39.Steinhubl S.R., Waalen J., Edwards A.M. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the MSTOPS randomized clinical trial. JAMA. 2018;320(2):146–155. doi: 10.1001/jama.2018.8102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Brunetti N.D., De Gennaro L., Pellegrino P.L., Dellegrottaglie G., Antonelli G., Di Biase M. Atrial fibrillation with symptoms other than palpitations: incremental diagnostic sensitivity with at-home tele-cardiology assessment for emergency medical service. Eur J Prev Cardiol. 2012;19(3):306–313. doi: 10.1177/1741826711406060. [DOI] [PubMed] [Google Scholar]
  • 41.American College of Cardiology Apple heart study identifies AFib in small group of Apple Watch wearers. https://www.acc.org/latest-in-cardiology/articles/2019/03/08/15/32/sat-9am-apple-heart-study-acc-2019/ Accessed September 12, 2019.
  • 42.Jencks S.F., Williams M.V., Coleman E.A. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med. 2009;360(14):1418–1428. doi: 10.1056/NEJMsa0803563. [DOI] [PubMed] [Google Scholar]
  • 43.heartfailurematters.org. Heart failure matters. https://www.heartfailurematters.org/en_GB/
  • 44.Seto E., Leonard K.J., Cafazzo J.A., Barnsley J., Masino C., Ross H.J. Mobile phone-based telemonitoring for heart failure management: a randomized controlled trial. J Med Internet Res. 2012;14(1):e31. doi: 10.2196/jmir.1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Dendale P., De Keulenaer G., Troisfontaines P. Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA-HF 1 (telemonitoring in the management of heart failure) study. Eur J Heart Fail. 2012;14(3):333–340. doi: 10.1093/eurjhf/hfr144. [DOI] [PubMed] [Google Scholar]
  • 46.Chaudhry S.I., Mattera J.A., Curtis J.P. Telemonitoring in patients with heart failure. N Engl J Med. 2010;363(24):2301–2309. doi: 10.1056/NEJMoa1010029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ledwidge M.T., O'Hanlon R., Lalor L. Can individualized weight monitoring using the heartphone algorithm improve sensitivity for clinical deterioration of heart failure? Eur J Heart Fail. 2013;15(4):447–455. doi: 10.1093/eurjhf/hfs186. [DOI] [PubMed] [Google Scholar]
  • 48.Anand I.S., Tang W.H., Greenberg B.H. Design and performance of a multisensor heart failure monitoring algorithm: results from the multisensor monitoring in congestive heart failure (music) study. J Card Fail. 2012;18(4):289–295. doi: 10.1016/j.cardfail.2012.01.009. [DOI] [PubMed] [Google Scholar]
  • 49.Sanchez-Ross M., Oghlakian G., Maher J. The STAT-MI (ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction) trial improves outcomes. JACC Cardiovasc Interv. 2011;4(2):222–227. doi: 10.1016/j.jcin.2010.11.007. [DOI] [PubMed] [Google Scholar]
  • 50.Johnston N., Bodegard J., Jerstrom S. Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: a randomized study. Am Heart J. 2016;178:85–94. doi: 10.1016/j.ahj.2016.05.005. [DOI] [PubMed] [Google Scholar]
  • 51.Chow C.K., Redfern J., Hillis G.S. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial. JAMA. 2015;314(12):1255–1263. doi: 10.1001/jama.2015.10945. [DOI] [PubMed] [Google Scholar]
  • 52.Tsai L.L., McNamara R.J., Moddel C., Alison J.A., McKenzie D.K., McKeough Z.J. Home-based telerehabilitation via real-time videoconferencing improves endurance exercise capacity in patients with copd: the randomized controlled teler study. Respirology. 2017;22(4):699–707. doi: 10.1111/resp.12966. [DOI] [PubMed] [Google Scholar]
  • 53.Vorrink S.N., Kort H.S., Troosters T., Zanen P., Lammers J.J. Efficacy of an mhealth intervention to stimulate physical activity in COPD patients after pulmonary rehabilitation. Eur Respir J. 2016;48(4):1019–1029. doi: 10.1183/13993003.00083-2016. [DOI] [PubMed] [Google Scholar]
  • 54.National Institutes of Health Clinical Center. Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis. NCT03562247. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. http://clinicaltrials.gov/ct2/show/NCT03562247. Updated August 6, 2018.
  • 55.Dalla Vecchia L.A., Bussotti M. Exercise training in pulmonary arterial hypertension. J Thorac Dis. 2018;10(1):508–521. doi: 10.21037/jtd.2018.01.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.National Institutes of Health Clinical Center. A Mobile Health Intervention in Pulmonary Arterial Hypertension. NCT03069716. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. http://clinicaltrials.gov/ct2/show/NCT03069716. Updated November 14, 2019.
  • 57.National Institutes of Health Clinical Center. Pulmonary hypertension, hypoxia, and sickle cell disease. NCT03617458. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. http://clinicaltrials.gov/ct2/show/NCT03617458. Updated November 20, 2019.
  • 58.Brooks G.C., Vittinghoff E., Iyer S. Accuracy and usability of a self-administered 6-minute walk test smartphone application. Circ Heart Fail. 2015;8(5):905–913. doi: 10.1161/CIRCHEARTFAILURE.115.002062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Goel K., Lennon R.J., Tilbury R.T., Squires R.W., Thomas R.J. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation. 2011;123(21):2344–2352. doi: 10.1161/CIRCULATIONAHA.110.983536. [DOI] [PubMed] [Google Scholar]
  • 60.Humen D., Higgins G., Unsworth K., Prior P., Massel D., Suskin N. A cost analysis of event reduction provided by a comprehensive cardiac rehabilitation program. Can J Cardiol. 2013;29(10):S156. [Google Scholar]
  • 61.Gomadam P.S., Douglas C.J., Sacrinty M.T., Brady M.M., Paladenech C.C., Robinson K.C. Degree and direction of change of body weight in cardiac rehabilitation and impact on exercise capacity and cardiac risk factors. Am J Cardiol. 2016;117(4):580–584. doi: 10.1016/j.amjcard.2015.11.045. [DOI] [PubMed] [Google Scholar]
  • 62.Ades P.A., Keteyian S.J., Wright J.S. Increasing cardiac rehabilitation participation from 20% to 70%: a road map from the million hearts cardiac rehabilitation collaborative. Mayo Clin Proc. 2017;92(2):234–242. doi: 10.1016/j.mayocp.2016.10.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Benjamin E.J., Muntner P., Alonso A. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528. doi: 10.1161/CIR.0000000000000659. [DOI] [PubMed] [Google Scholar]
  • 64.Balady G.J., Ades P.A., Bittner V.A. Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation. 2011;124(25):2951–2960. doi: 10.1161/CIR.0b013e31823b21e2. [DOI] [PubMed] [Google Scholar]
  • 65.Dunlay S.M., Witt B.J., Allison T.G. Barriers to participation in cardiac rehabilitation. Am Heart J. 2009;158(5):852–859. doi: 10.1016/j.ahj.2009.08.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Varnfield M., Karunanithi M., Lee C.K. Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomised controlled trial. Heart. 2014;100(22):1770–1779. doi: 10.1136/heartjnl-2014-305783. [DOI] [PubMed] [Google Scholar]
  • 67.Whittaker F., Wade V. The costs and benefits of technology-enabled, home-based cardiac rehabilitation measured in a randomised controlled trial. J Telemed Telecare. 2014;20(7):419–422. doi: 10.1177/1357633X14552376. [DOI] [PubMed] [Google Scholar]
  • 68.Widmer R.J., Allison T.G., Lennon R., Lopez-Jimenez F., Lerman L.O., Lerman A. Digital health intervention during cardiac rehabilitation: a randomized controlled trial. Am Heart J. 2017;188:65–72. doi: 10.1016/j.ahj.2017.02.016. [DOI] [PubMed] [Google Scholar]
  • 69.Swarup S., Makaryus A.N. Digital stethoscope: technology update. Med Devices (Auckl) 2018;11:29–36. doi: 10.2147/MDER.S135882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Becker C., Fusaro M., Patel D., Shalom I., Frishman W.H., Scurlock C. The utility of teleultrasound to guide acute patient management. Cardiol Rev. 2017;25(3):97–101. doi: 10.1097/CRD.0000000000000144. [DOI] [PubMed] [Google Scholar]
  • 71.Downey C., Randell R., Brown J., Jayne D.G. Continuous versus intermittent vital signs monitoring using a wearable, wireless patch in patients admitted to surgical wards: pilot cluster randomized controlled trial. J Med Internet Res. 2018;20(12) doi: 10.2196/10802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Weenk M., Koeneman M., van de Belt T.H., Engelen L., van Goor H., Bredie S.J.H. Wireless and continuous monitoring of vital signs in patients at the general ward. Resuscitation. 2019;136:47–53. doi: 10.1016/j.resuscitation.2019.01.017. [DOI] [PubMed] [Google Scholar]
  • 73.Izmailova E.S., Wagner J.A., Perakslis E.D. Wearable devices in clinical trials: hype and hypothesis. Clin Pharmacol Ther. 2018;104(1):42–52. doi: 10.1002/cpt.966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Avram R., Tison G.H., Aschbacher K. Real-world heart rate norms in the health eheart study. NPJ Digit Med. 2019;2:58. doi: 10.1038/s41746-019-0134-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.McConnell M.V., Shcherbina A., Pavlovic A. Feasibility of obtaining measures of lifestyle from a smartphone app: the MyHeart counts cardiovascular health study. JAMA Cardiol. 2017;2(1):67–76. doi: 10.1001/jamacardio.2016.4395. [DOI] [PubMed] [Google Scholar]
  • 76.McLean A. Apple researchkit and carekit. Can J Nurs Inform. 2019;14(1) [Google Scholar]
  • 77.Urban JM, Hoofnagle CJ, Li S. Mobile phones and privacy. CLT Research Paper Series; UC Berkeley Public Law Research Paper No. 2103405.
  • 78.Grundy Q., Chiu K., Held F., Continella A., Bero L., Holz R. Data sharing practices of medicines related apps and the mobile ecosystem: traffic, content, and network analysis. BMJ. 2019;364:I920. doi: 10.1136/bmj.l920. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Chest are provided here courtesy of American College of Chest Physicians

RESOURCES